Brief: Acer Therapeutics And Relief Therapeutics Announce FDA Acceptance For NDA For Urea Cycle Disorders Treatment

MindMaze Therapeutics Holding SA

06/10/2021 13:49

Oct 6 (Reuters) - Acer Therapeutics Inc  ACER.O :
    * ACER THERAPEUTICS AND RELIEF THERAPEUTICS ANNOUNCE FDA
ACCEPTANCE FOR FILING OF NEW DRUG APPLICATION FOR ACER-001 TO
TREAT UREA CYCLE DISORDERS
    * ACER THERAPEUTICS AND RELIEF THERAPEUTICS ANNOUNCE FDA
ACCEPTANCE FOR FILING OF NEW DRUG APPLICATION FOR ACER-001 TO
TREAT UREA CYCLE DISORDERS
    * ACER THERAPEUTICS INC - FDA HAS ASSIGNED A PRESCRIPTION
DRUG
USER FEE ACT (PDUFA) TARGET ACTION DATE OF JUNE 5, 2022

Source text for Eikon:  ID:nGNX2873nZ 
Further company coverage:  ACER.O 

 ((Reuters.Briefs@thomsonreuters.com;))